Brief: Apontis Pharma 9M Adjusted EBITDA Up At EUR 4.4 Mln

Apontis Pharma AG

18/11/2021 06:34

Nov 18 (Reuters) - APONTIS PHARMA AG  APPHG.DE :
    * APONTIS PHARMA GROWS SIGNIFICANTLY FASTER THAN THE OVERALL
MARKET IN THE NINE-MONTH PERIOD 2021 - REVENUE FORECAST
INCREASED
    * 9M EBITDA (ADJUSTED) INCREASES SIGNIFICANTLY BY EUR 5.7
MILLION
TO EUR 4.4 MILLION WITH ONLY DISPROPORTIONATELY LOW COST
DEVELOPMENT
    * 9M REVENUE ROSE 37 PERCENT TO 36.7 MILLION EUR
    * TOTAL OF FOUR NEW SINGLE PILL LAUNCHES PLANNED FOR 2022
    * REVENUES FORECAST 2021 INCREASED TO UP TO EUR 49.5 MILLION
(INITIALLY EUR 48.5 MILLION), EBITDA ADJUSTED CONFIRMED

Source text for Eikon:  ID:nEQ8wt5wDa 
Further company coverage:  APPHG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))